|
1
|
Ghafouri-Fard S, Khoshbakht T, Hussen BM, Dong P, Gassler N, Taheri M, Baniahmad A, Dilmaghani NA. A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int 2022; 22:325. [PMID: 36266723 PMCID: PMC9583502 DOI: 10.1186/s12935-022-02747-z] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2022] [Accepted: 10/07/2022] [Indexed: 11/16/2022] Open
Abstract
The Cyclin-dependent kinase (CDK) class of serine/threonine kinases has crucial roles in the regulation of cell cycle transition and is mainly involved in the pathogenesis of cancers. The expression of CDKs is controlled by a complex regulatory network comprised of genetic and epigenetic mechanisms, which are dysregulated during the progression of cancer. The abnormal activation of CDKs results in uncontrolled cancer cell proliferation and the induction of cancer stem cell characteristics. The levels of CDKs can be utilized to predict the prognosis and treatment response of cancer patients, and further understanding of the function and underlying mechanisms of CDKs in human tumors would pave the way for future cancer therapies that effectively target CDKs. Defects in the regulation of cell cycle and mutations in the genes coding cell-cycle regulatory proteins lead to unrestrained proliferation of cells leading to formation of tumors. A number of treatment modalities have been designed to combat dysregulation of cell cycle through affecting expression or activity of CDKs. However, effective application of these methods in the clinical settings requires recognition of the role of CDKs in the progression of each type of cancer, their partners, their interactions with signaling pathways and the effects of suppression of these kinases on malignant features. Thus, we designed this literature search to summarize these findings at cellular level, as well as in vivo and clinical levels.
Collapse
Affiliation(s)
- Soudeh Ghafouri-Fard
- Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Tayyebeh Khoshbakht
- Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Bashdar Mahmud Hussen
- Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, Erbil, Kurdistan Region, Iraq.,Center of Research and Strategic Studies, Lebanese French University, Erbil, Kurdistan Region, Iraq
| | - Peixin Dong
- Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Hokkaido University, Sapporo, Japan
| | - Nikolaus Gassler
- Section of Pathology, Institute of Forensic Medicine, Jena University Hospital, Jena, Germany
| | - Mohammad Taheri
- Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. .,Institute of Human Genetics, Jena University Hospital, Jena, Germany.
| | - Aria Baniahmad
- Institute of Human Genetics, Jena University Hospital, Jena, Germany.
| | - Nader Akbari Dilmaghani
- Skull Base Research Center, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
|
2
|
Piao XM, You C, Byun YJ, Kang HW, Noh J, Lee J, Lee HY, Kim K, Kim WT, Yun SJ, Lee SC, Kang K, Kim YJ. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression. Int J Mol Sci 2021; 22:ijms222312756. [PMID: 34884561 PMCID: PMC8657483 DOI: 10.3390/ijms222312756] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2021] [Revised: 11/22/2021] [Accepted: 11/23/2021] [Indexed: 11/18/2022] Open
Abstract
Non-muscle-invasive bladder cancer (NMIBC) is a common disease with a high recurrence rate requiring lifetime surveillance. Although NMIBC is not life-threatening, it can progress to muscle-invasive bladder cancer (MIBC), a lethal form of the disease. The management of the two diseases differs, and patients with MIBC require aggressive treatments such as chemotherapy and radical cystectomy. NMIBC patients at a high risk of progression benefit from early immediate cystectomy. Thus, identifying concordant markers for accurate risk stratification is critical to predict the prognosis of NMIBC. Candidate genetic biomarkers associated with NMIBC prognosis were screened by RNA-sequencing of 24 tissue samples, including 16 NMIBC and eight normal controls, and by microarray analysis (GSE13507). Lastly, we selected and investigated a mitotic checkpoint serine/threonine kinase, BUB1, that regulates chromosome segregation during the cell cycle. BUB1 gene expression was tested in 86 NMIBC samples and 15 controls by real-time qPCR. The performance of BUB1 as a prognostic biomarker for NMIBC was validated in the internal Chungbuk cohort (GSE13507) and the external UROMOL cohort (E-MTAB-4321). BUB1 expression was higher in NMIBC patients than in normal controls (p < 0.05), and the overexpression of BUB1 was correlated with NMIBC progression (log-rank test, p = 0.007). In in vitro analyses, BUB1 promoted the proliferation of bladder cancer cells by accelerating the G2/M transition of the cell cycle. Conclusively, BUB1 modulates the G2/M transition to promote the proliferation of bladder cancer cells, suggesting that it could serve as a prognostic marker in NMIBC.
Collapse
Affiliation(s)
- Xuan-Mei Piao
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
| | - Chaelin You
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea; (C.Y.); (J.N.); (J.L.)
| | - Young Joon Byun
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
| | - Ho Won Kang
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Junho Noh
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea; (C.Y.); (J.N.); (J.L.)
| | - Jaehyun Lee
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea; (C.Y.); (J.N.); (J.L.)
| | - Hee Youn Lee
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Kyeong Kim
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Won Tae Kim
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Seok Joong Yun
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Sang-Cheol Lee
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
| | - Kyuho Kang
- Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju 28644, Korea; (C.Y.); (J.N.); (J.L.)
- Correspondence: (K.K.); (Y.-J.K.); Tel.: +82-43-261-2295 (K.K.); +82-43-269-6143 (Y.-J.K.)
| | - Yong-June Kim
- Department of Urology, College of Medicine, Chungbuk National University, Cheongju 28644, Korea; (X.-M.P.); (Y.J.B.); (H.W.K.); (W.T.K.); (S.J.Y.); (S.-C.L.)
- Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea; (H.Y.L.); (K.K.)
- Correspondence: (K.K.); (Y.-J.K.); Tel.: +82-43-261-2295 (K.K.); +82-43-269-6143 (Y.-J.K.)
| |
Collapse
|
|
3
|
Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis. Expert Rev Anticancer Ther 2021; 21:795-803. [PMID: 33764838 DOI: 10.1080/14737140.2021.1908132] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Abnormal BUB1B expression has been proven to be related to the poor prognosis of various tumors. This meta-analysis aimed to identify the prognostic role of BUB1B in patients with lung adenocarcinoma (LUAD). RESEARCH DESIGN AND METHODS Relevant studies from the PubMed, Embase, Web of Science, and Cochrane Library databases and two public databases that stored sequencing data were retrieved. The standardized mean difference (SMD) and 95% confidence intervals (CIs) for the association between the BUB1B expression level and clinical characteristics were calculated. Pooled hazard ratios (HRs) and 95% CIs were calculated to estimate the association between BUB1B expression and survival outcomes. RESULTS A total of 16 studies involving 2771 LUAD patients with BUB1B expression were included in this meta-analysis. Patients with older age showed low BUB1B expression. High BUB1B expression was associated with male sex, a smoking history, and an advanced TNM stage. High BUB1B expression was predictive of poor overall survival (OS) and progression-free survival (PFS). In addition, no publication bias was found. CONCLUSIONS This meta-analysis demonstrates that BUB1B is a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with LUAD.
Collapse
Affiliation(s)
- Jie Chen
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.,Inflammation & Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, China.,Office of Disciplines Construction & Academic Degree, Graduate School of Southwest Medical University, Luzhou, China
| | - Yi Liao
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.,Inflammation & Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| | - Xianming Fan
- Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.,Inflammation & Allergic Diseases Research Unit, The Affiliated Hospital of Southwest Medical University, Luzhou, China
| |
Collapse
|